|
1
|
Maomao C, He L, Dianqin S, Siyi H, Xinxin
Y, Fan Y, Shaoli Z, Changfa X, Lin L, Ji P and Wanqing C: Current
cancer burden in China: Epidemiology, etiology, and prevention.
Cancer Biol Med. 19:1121–1138. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Roy PS and Saikia BJ: Cancer and cure: A
critical analysis. Indian J Cancer. 53:441–442. 2016. View Article : Google Scholar
|
|
3
|
Sobhani N, Scaggiante B, Morris R, Chai D,
Catalano M, Tardiel-Cyril DR, Neeli P, Roviello G, Mondani G and Li
Y: Therapeutic cancer vaccines: From biological mechanisms and
engineering to ongoing clinical trials. Cancer Treat Rev.
109:1024292022. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Corbett KS, F lynn B, Foulds K E, Francica
J R, Boyoglu-Barnum S, Werner AP, Flach B, O'Connell S, Bock KW,
Minai M, et al: Evaluation of the mRNA-1273 Vaccine against
SARS-CoV-2 in Nonhuman Primates. N Engl J Med. 383:1544–1555. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Scherubl H: Smoking tobacco and cancer
risk. Dtsch Med Wochenschr. 146:412–417. 2021.In German.
|
|
6
|
van Elsland D and Neefjes J: Bacterial
infections and cancer. EMBO Rep. 19:e466322018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Schiller JT and Lowy DR: An introduction
to virus infections and human cancer. Recent Results Cancer Res.
217:1–11. 2021. View Article : Google Scholar :
|
|
8
|
Zare Sakhvidi MJ, Lequy E, Goldberg M and
Jacquemin B: Air pollution exposure and bladder, kidney and urinary
tract cancer risk: A systematic review. Environ Pollut.
267:1153282020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yuan Y, Gao F, Chang Y, Zhao Q and He X:
Advances of mRNA vaccine in tumor: A maze of opportunities and
challenges. Biomark Res. 11:62023. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gote V, Bolla PK, Kommineni N, Butreddy A,
Nukala PK, Palakurthi SS and Khan W: A comprehensive review of mRNA
Vaccines. Int J Mol Sci. 24:27002023. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Deng Z, Tian Y, Song J, An G and Yang P:
mRNA Vaccines: The dawn of a new era of cancer immunotherapy. Front
Immunol. 13:8871252022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu C, Shi Q, Huang X, Koo S, Kong N and
Tao W: mRNA-based cancer therapeutics. Nat Rev Cancer. 23:526–543.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lorentzen CL, Haanen JB, Met Ö and Svane
IM: Clinical advances and ongoing trials on mRNA vaccines for
cancer treatment. Lancet Oncol. 23:e450–e458. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Weber JS, Carlino MS, Khattak A, Meniawy
T, Ansstas G, Taylor MH, Kim KB, McKean M, Long GV, Sullivan RJ, et
al: Individualised neoantigen therapy mRNA-4157 (V940) plus
pembrolizumab versus pembrolizumab monotherapy in resected melanoma
(KEYNOTE-942): A randomised, phase 2b study. Lancet. 403:632–644.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Siegel RL, Miller KD, Wagle NS and Jemal
A: Cancer statistics, 2023. CA Cancer J Clin. 73:17–48. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kaur R, Bhardwaj A and Gupta S: Cancer
treatment therapies: Traditional to modern approaches to combat
cancers. Mol Biol Rep. 50:9663–9676. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sahin U and Tureci O: Personalized
vaccines for cancer immunotherapy. Science. 359:1355–1360. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Saxena M, van der Burg SH, Melief CJM and
Bhardwaj N: Therapeutic cancer vaccines. Nat Rev Cancer.
21:360–378. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li Y, Wang M, Peng X, Yang Y, Chen Q, Liu
J, She Q, Tan J, Lou C, Liao Z and Li X: mRNA vaccine in cancer
therapy: Current advance and future outlook. Clin Transl Med.
13:e13842023. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fang E, Liu X, Li M, Zhang Z, Song L, Zhu
B, Wu X, Liu J, Zhao D and Li Y: Advances in COVID-19 mRNA vaccine
development. Signal Transduct Target Ther. 7:942022. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Szabo GT, Mahiny AJ and Vlatkovic I:
COVID-19 mRNA vaccines: Platforms and current developments. Mol
Ther. 30:1850–1868. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Brenner S, Jacob F and Meselson M: An
unstable intermediate carrying information from genes to ribosomes
for protein synthesis. Nature. 190:576–581. 1961. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Malone RW, Felgner PL and Verma IM:
Cationic liposome-mediated RNA transfection. Proc Natl Acad Sci
USA. 86:6077–6081. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wolff JA, Malone RW, Williams P, Chong W,
Acsadi G, Jani A and Felgner PL: Direct gene transfer into mouse
muscle in vivo. Science. 247(4949 Pt 1): 1465–1468. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jirikowski GF, Sanna PP,
Maciejewski-Lenoir D and Bloom FE: Reversal of diabetes insipidus
in Brattleboro rats: Intrahypothalamic injection of vasopressin
mRNA. Science. 255:996–998. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Martinon F, Krishnan S, Lenzen G, Magné R,
Gomard E, Guillet JG, Lévy JP and Meulien P: Induction of
virus-specific cytotoxic T lymphocytes in vivo by
liposome-entrapped mRNA. Eur J Immunol. 23:1719–1722. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Boczkowski D, Nair SK, Snyder D and Gilboa
E: Dendritic cells pulsed with RNA are potent antigen-presenting
cells in vitro and in vivo. J Exp Med. 184:465–472. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhou WZ, Hoon DS, Huang SK, Fujii S,
Hashimoto K, Morishita R and Kaneda Y: RNA melanoma vaccine:
induction of antitumor immunity by human glycoprotein 100 mRNA
immunization. Hum Gene Ther. 10:2719–2724. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang Y, Zhang Z, Luo J, Han X, Wei Y and
Wei X: mRNA vaccine: A potential therapeutic strategy. Mol Cancer.
20:332021. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wadhwa A, Aljabbari A, Lokras A, Foged C
and Thakur A: Opportunities and Challenges in the Delivery of
mRNA-based Vaccines. Pharmaceutics. 12:1022020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kackos CM, Surman SL, Jones BG, Sealy RE,
Jeevan T, Davitt CJH, Pustylnikov S, Darling TL, Boon ACM, Hurwitz
JL, et al: mRNA Vaccine Mitigates SARS-CoV-2 Infections and
COVID-19. Microbiol Spectr. 11:e04240222023. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Park JW, Lagniton PNP, Liu Y and Xu RH:
mRNA vaccines for COVID-19: What, why and how. Int J Biol Sci.
17:1446–1460. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gong H, Wen J, Luo R, Feng Y, Guo J, Fu H
and Zhou X: Integrated mRNA sequence optimization using deep
learning. Brief Bioinform. 24:bbad0012023. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pardi N, Hogan MJ, Porter FW and Weissman
D: mRNA vaccines-a new era in vaccinology. Nat Rev Drug Discov.
17:261–279. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Herrera M, Kim J, Eygeris Y, Jozic A and
Sahay G: Illuminating endosomal escape of polymorphic lipid
nanoparticles that boost mRNA delivery. Biomater Sci. 9:4289–4300.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Jyotsana N, Sharma A, Chaturvedi A, Budida
R, Scherr M, Kuchenbauer F, Lindner R, Noyan F, Sühs KW, Stangel M,
et al: Lipid nanoparticle-mediated siRNA delivery for safe
targeting of human CML in vivo. Ann Hematol. 98:1905–1918. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sahin U, Kariko K and Tureci O: mRNA-based
therapeutics-developing a new class of drugs. Nat Rev Drug Discov.
13:759–780. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Cruz FM, Chan A and Rock KL: Pathways of
MHC I cross-presentation of exogenous antigens. Semin Immunol.
66:1017292023. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Rosa SS, Prazeres DMF, Azevedo AM and
Marques MPC: mRNA vaccines manufacturing: Challenges and
bottlenecks. Vaccine. 39:2190–2200. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Xu S, Yang K, Li R and Zhang L: mRNA
Vaccine Era-Mechanisms, drug platform and clinical prospection. Int
J Mol Sci. 21:20202020. View Article : Google Scholar
|
|
41
|
Talotta R: Do COVID-19 RNA-based vaccines
put at risk of immune-mediated diseases? In reply to 'potential
antigenic cross-reactivity between SARS-CoV-2 and human tissue with
a possible link to an increase in autoimmune diseases'. Clin
Immunol. 224:1086652021. View Article : Google Scholar
|
|
42
|
Chen YG and Hur S: Cellular origins of
dsRNA, their recognition and consequences. Nat Rev Mol Cell Biol.
23:286–301. 2022. View Article : Google Scholar :
|
|
43
|
Vaidyanathan S, Azizian KT, Haque AKMA,
Henderson JM, Hendel A, Shore S, Antony JS, Hogrefe RI, Kormann
MSD, Porteus MH and McCaffrey AP: Uridine depletion and chemical
modification increase Cas9 mRNA activity and reduce immunogenicity
without HPLC purification. Mol Ther Nucleic Acids. 12:530–542.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Bernardo M, Tolstykh T, Zhang YA, Bangari
DS, Cao H, Heyl KA, Lee JS, Malkova NV, Malley K, Marquez E, et al:
An experimental model of anti-PD-1 resistance exhibits activation
of TGFβ and Notch pathways and is sensitive to local mRNA
immunotherapy. Oncoimmunology. 10:18812682021. View Article : Google Scholar
|
|
45
|
Yao R, Xie C and Xia X: Recent progress in
mRNA cancer vaccines. Hum Vaccin Immunother. 20:23071872024.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wilson RC and Carroll D: The daunting
economics of therapeutic genome editing. CRISPR J. 2:280–284. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Morrison C: $1-million price tag set for
Glybera gene therapy. Nat Biotechnol. 33:217–218. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Jackson NAC, Kester KE, Casimiro D,
Gurunathan S and DeRosa F: The promise of mRNA vaccines: A biotech
and industrial perspective. NPJ Vaccines. 5:112020. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Miao L, Zhang Y and Huang L: mRNA vaccine
for cancer immunotherapy. Mol Cancer. 20:412021. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Ita K: Coronavirus Disease (COVID-19):
Current status and prospects for drug and vaccine development. Arch
Med Res. 52:15–24. 2021. View Article : Google Scholar :
|
|
51
|
Van Nuffel AM, Wilgenhof S, Thielemans K
and Bonehill A: Overcoming HLA restriction in clinical trials:
Immune monitoring of mRNA-loaded DC therapy. Oncoimmunology.
1:1392–1394. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Ho W, Gao M, Li F, Li Z, Zhang XQ and Xu
X: Next-Generation Vaccines: Nanoparticle-Mediated DNA and mRNA
Delivery. Adv Healthc Mater. 10:e20018122021. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Guevara ML, Persano F and Persano S:
Advances in lipid nanoparticles for mRNA-Based cancer
immunotherapy. Front Chem. 8:5899592020. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
De Beuckelaer A, Grooten J and De Koker S:
Type I Interferons Modulate CD8(+) T Cell Immunity to mRNA
Vaccines. Trends Mol Med. 23:216–226. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Karam M and Daoud G: mRNA vaccines: Past,
present, future. Asian J Pharm Sci. 17:491–522. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Zhao P, Hou X, Yan J, Du S, Xue Y, Li W,
Xiang G and Dong Y: Long-term storage of lipid-like nanoparticles
for mRNA delivery. Bioact Mater. 5:358–363. 2020.PubMed/NCBI
|
|
57
|
Stitz L, Vogel A, Schnee M, Voss D, Rauch
S, Mutzke T, Ketterer T, Kramps T and Petsch B: A thermostable
messenger RNA based vaccine against rabies. PLoS Negl Trop Dis.
11:e00061082017. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Petsch B, Schnee M, Vogel AB, Lange E,
Hoffmann B, Voss D, Schlake T, Thess A, Kallen KJ, Stitz L and
Kramps T: Protective efficacy of in vitro synthesized, specific
mRNA vaccines against influenza A virus infection. Nat Biotechnol.
30:1210–1216. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Dowdy SF: Overcoming cellular barriers for
RNA therapeutics. Nat Biotechnol. 35:222–229. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Chaudhary N, Weissman D and Whitehead KA:
mRNA vaccines for infectious diseases: principles, delivery and
clinical translation. Nat Rev Drug Discov. 20:817–838. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Heine A, Juranek S and Brossart P:
Clinical and immunological effects of mRNA vaccines in malignant
diseases. Mol Cancer. 20:522021. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Schlake T, Thess A, Fotin-Mleczek M and
Kallen KJ: Developing mRNA-vaccine technologies. RNA Biol.
9:1319–1330. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Dobrowolski C, Paunovska K, Schrader
Echeverri E, Loughrey D, Da Silva Sanchez AJ, Ni H, Hatit MZC,
Lokugamage MP, Kuzminich Y, Peck HE, et al: Nanoparticle
single-cell multiomic readouts reveal that cell heterogeneity
influences lipid nanoparticle-mediated messenger RNA delivery. Nat
Nanotechnol. 17:871–879. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Solodushko V and Fouty B: Terminal
hairpins improve protein expression in IRES-initiated mRNA in the
absence of a cap and polyadenylated tail. Gene Ther. 30:620–627.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Kowalski PS, Rudra A, Miao L and Anderson
DG: Delivering the messenger: Advances in technologies for
therapeutic mRNA delivery. Mol Ther. 27:710–728. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Park KS, Sun X, Aikins ME and Moon JJ:
Non-viral COVID-19 vaccine delivery systems. Adv Drug Deliv Rev.
169:137–151. 2021. View Article : Google Scholar
|
|
67
|
Kim J, Eygeris Y, Gupta M and Sahay G:
Self-assembled mRNA vaccines. Adv Drug Deliv Rev. 170:83–112. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Kauffman KJ, Webber MJ and Anderson DG:
Materials for non-viral intracellular delivery of messenger RNA
therapeutics. J Control Release. 240:227–234. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Whitley J, Zwolinski C, Denis C, Maughan
M, Hayles L, Clarke D, Snare M, Liao H, Chiou S, Marmura T, et al:
Development of mRNA manufacturing for vaccines and therapeutics:
mRNA platform requirements and development of a scalable production
process to support early phase clinical trials. Transl Res.
242:38–55. 2022. View Article : Google Scholar
|
|
70
|
Kariko K, Muramatsu H, Ludwig J and
Weissman D: Generating the optimal mRNA for therapy: HPLC
purification eliminates immune activation and improves translation
of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Res.
39:e1422011. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Linares-Fernandez S, Lacroix C, Exposito
JY and Verrier B: Tailoring mRNA vaccine to balance innate/adaptive
immune response. Trends Mol Med. 26:311–323. 2020. View Article : Google Scholar
|
|
72
|
Engel BJ, Grindel BJ, Gray JP and Millward
SW: Purification of poly-dA oligonucleotides and mRNA-protein
fusions with dT(25)-OAS resin. Bioorg Med Chem Lett. 30:1269342020.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Ye Z, Harmon J, Ni W, Li Y, Wich D and Xu
Q: The mRNA Vaccine Revolution: COVID-19 has launched the future of
vaccinology. ACS Nano. 17:15231–15253. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
To KKW and Cho WCS: An overview of
rational design of mRNA-based therapeutics and vaccines. Expert
Opin Drug Discov. 16:1307–1317. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Kariko K, Kuo A and Barnathan E:
Overexpression of urokinase receptor in mammalian cells following
administration of the in vitro transcribed encoding mRNA. Gene
Ther. 6:1092–1100. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Kallen KJ and Theβ A: A development that
may evolve into a revolution in medicine: mRNA as the basis for
novel, nucleotide-based vaccines and drugs. Ther Adv Vaccines.
2:10–31. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Holtkamp S, Kreiter S, Selmi A, Simon P,
Koslowski M, Huber C, Türeci O and Sahin U: Modification of
antigen-encoding RNA increases stability, translational efficacy,
and T-cell stimulatory capacity of dendritic cells. Blood.
108:4009–4017. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Leppek K, Byeon GW, Kladwang W,
Wayment-Steele HK, Kerr CH, Xu AF, Kim DS, Topkar VV, Choe C,
Rothschild D, et al: Combinatorial optimization of mRNA structure,
stability, and translation for RNA-based therapeutics. Nat Commun.
13:15362022. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Ramanathan A, Robb GB and Chan SH: mRNA
capping: Biological functions and applications. Nucleic Acids Res.
44:7511–7526. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Li Y and Kiledjian M: Regulation of mRNA
decapping. Wiley Interdiscip Rev RNA. 1:253–265. 2010. View Article : Google Scholar
|
|
81
|
Geall AJ, Verma A, Otten GR, Shaw CA,
Hekele A, Banerjee K, Cu Y, Beard CW, Brito LA, Krucker T, et al:
Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad
Sci USA. 109:14604–14609. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Mohamad Razif MI, Nizar N, Zainal Abidin
NH, Muhammad Ali SN, Wan Zarimi WNN, Khotib J, Susanti D, Mohd
Jailani MT and Taher M: Emergence of mRNA vaccines in the
management of cancer. Expert Rev Vaccines. 22:629–642. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Kim SC, Sekhon SS, Shin WR, Ahn G, Cho BK,
Ahn JY and Kim YH: Modifications of mRNA vaccine structural
elements for improving mRNA stability and translation efficiency.
Mol Cell Toxicol. 18:1–8. 2022. View Article : Google Scholar
|
|
84
|
Warminski M, Kowalska J, Nowak E, Kubacka
D, Tibble R, Kasprzyk R, Sikorski PJ, Gross JD, Nowotny M and
Jemielity J: Structural Insights into the interaction of clinically
relevant phosphorothioate mRNA Cap Analogs with translation
initiation factor 4E Reveal Stabilization via Electrostatic
Thio-Effect. ACS Chem Biol. 16:334–343. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Kuhn AN, Diken M, Kreiter S, Selmi A,
Kowalska J, Jemielity J, Darzynkiewicz E, Huber C, Türeci O and
Sahin U: Phosphorothioate cap analogs increase stability and
translational efficiency of RNA vaccines in immature dendritic
cells and induce superior immune responses in vivo. Gene Ther.
17:961–971. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Grudzien-Nogalska E, Jemielity J, Kowalska
J, Darzynkiewicz E and Rhoads RE: Phosphorothioate cap analogs
stabilize mRNA and increase translational efficiency in mammalian
cells. RNA. 13:1745–1755. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Rydzik AM, Kulis M, Lukaszewicz M,
Kowalska J, Zuberek J, Darzynkiewicz ZM, Darzynkiewicz E and
Jemielity J: Synthesis and properties of mRNA cap analogs
containing imidodiphosphate moiety-fairly mimicking natural cap
structure, yet resistant to enzymatic hydrolysis. Bioorg Med Chem.
20:1699–1710. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Henderson JM, Ujita A, Hill E,
Yousif-Rosales S, Smith C, Ko N, McReynolds T, Cabral CR,
Escamilla-Powers JR and Houston ME: Cap 1 Messenger RNA Synthesis
with Co-transcriptional CleanCap((R)) Analog by In Vitro
Transcription. Curr Protoc. 1:e392021. View Article : Google Scholar
|
|
89
|
Suknuntha K, Tao L, Brok-Volchanskaya V,
D'Souza SS, Kumar A and Slukvin I: Optimization of Synthetic mRNA
for highly efficient translation and its application in the
generation of endothelial and hematopoietic cells from human and
primate pluripotent stem cells. Stem Cell Rev Rep. 14:525–534.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Ryczek N, Lys A and Makalowska I: The
Functional Meaning of 5'UTR in Protein-Coding Genes. Int J Mol Sci.
24:29762023. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Creusot RJ, Chang P, Healey DG,
Tcherepanova IY, Nicolette CA and Fathman CG: A short pulse of IL-4
delivered by DCs electroporated with modified mRNA can both prevent
and treat autoimmune diabetes in NOD mice. Mol Ther. 18:2112–2120.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Asrani KH, Farelli JD, Stahley MR, Miller
RL, Cheng CJ, Subramanian RR and Brown JM: Optimization of mRNA
untranslated regions for improved expression of therapeutic mRNA.
RNA Biol. 15:756–762. 2018.PubMed/NCBI
|
|
93
|
Chakraborty C, Sharma AR, Bhattacharya M
and Lee SS: From COVID-19 to Cancer mRNA Vaccines: Moving from
bench to clinic in the vaccine landscape. Front Immunol.
12:6793442021. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Beaudoin CA, Bartas M, Volná A, Pečinka P
and Blundell TL: Are There Hidden Genes in DNA/RNA Vaccines? Front
Immunol. 13:8019152022. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Gustafsson C, Govindarajan S and Minshull
J: Codon bias and heterologous protein expression. Trends
Biotechnol. 22:346–353. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Passmore LA and Coller J: Roles of mRNA
poly(A) tails in regulation of eukaryotic gene expression. Nat Rev
Mol Cell Biol. 23:93–106. 2022. View Article : Google Scholar
|
|
97
|
Lima SA, Chipman LB, Nicholson AL, Chen
YH, Yee BA, Yeo GW, Coller J and Pasquinelli AE: Short poly(A)
tails are a conserved feature of highly expressed genes. Nat Struct
Mol Biol. 24:1057–1063. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
McNamara MA, Nair SK and Holl EK:
RNA-Based Vaccines in Cancer Immunotherapy. J Immunol Res.
2015:7945282015. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Chung JY, Thone MN and Kwon YJ: COVID-19
vaccines: The status and perspectives in delivery points of view.
Adv Drug Deliv Rev. 170:1–25. 2021. View Article : Google Scholar
|
|
100
|
Islam MA, Rice J, Reesor E, Zope H, Tao W,
Lim M, Ding J, Chen Y, Aduluso D, Zetter BR, et al: Adjuvant-pulsed
mRNA vaccine nanoparticle for immunoprophylactic and therapeutic
tumor suppression in mice. Biomaterials. 266:1204312021. View Article : Google Scholar
|
|
101
|
De Keersmaecker B, Claerhout S, Carrasco
J, Bar I, Corthals J, Wilgenhof S, Neyns B and Thielemans K: TriMix
and tumor antigen mRNA electroporated dendritic cell vaccination
plus ipilimumab: link between T-cell activation and clinical
responses in advanced melanoma. J Immunother Cancer. 8:e0003292020.
View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Franzoni G, Anfossi A, De Ciucis CG,
Mecocci S, Carta T, Dei Giudici S, Fruscione F, Zinellu S, Vito G,
Graham SP, et al: Targeting Toll-Like Receptor 2: Polarization of
Porcine Macrophages by a Mycoplasma-Derived Pam2cys Lipopeptide.
Vaccines (Basel). 9:6922021. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Gu Y, Yang J, He C, Zhao T, Lu R, Liu J,
Mo X, Wen F and Shi H: Incorporation of a Toll-like receptor 2/6
agonist potentiates mRNA vaccines against cancer and infectious
diseases. Signal Transduct Target Ther. 8:2732023. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Ulmer JB, Mason PW, Geall A and Mandl CW:
RNA-based vaccines. Vaccine. 30:4414–4418. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
McCullough KC, Milona P, Thomann-Harwood
L, Démoulins T, Englezou P, Suter R and Ruggli N: Self-Amplifying
Replicon RNA Vaccine Delivery to Dendritic Cells by Synthetic
Nanoparticles. Vaccines (Basel). 2:735–754. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Maruggi G, Zhang C, Li J, Ulmer JB and Yu
D: mRNA as a transformative technology for vaccine development to
control infectious diseases. Mol Ther. 27:757–772. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Zhuang X, Qi Y, Wang M, Yu N, Nan F, Zhang
H, Tian M, Li C, Lu H and Jin N: mRNA Vaccines Encoding the HA
Protein of Influenza A H1N1 virus delivered by cationic lipid
nanoparticles induce protective immune responses in mice. Vaccines
(Basel). 8:1232020. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Kallen KJ, Heidenreich R, Schnee M, Petsch
B, Schlake T, Thess A, Baumhof P, Scheel B, Koch SD and
Fotin-Mleczek M: A novel, disruptive vaccination technology:
Self-adjuvanted RNActive((R)) vaccines. Hum Vaccin Immunother.
9:2263–2276. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Leal L, Guardo AC, Morón-López S, Salgado
M, Mothe B, Heirman C, Pannus P, Vanham G, van den Ham HJ, Gruters
R, et al: Phase I clinical trial of an intranodally administered
mRNA-based therapeutic vaccine against HIV-1 infection. AIDS.
32:2533–2545. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Jong W, Leal L, Buyze J, Pannus P, Guardo
A, Salgado M, Mothe B, Molto J, Moron-Lopez S, Gálvez C, et al:
Therapeutic Vaccine in Chronically HIV-1-Infected Patients: A
Randomized, Double-Blind, Placebo-Controlled Phase IIa Trial with
HTI-TriMix. Vaccines (Basel). 7:2092019. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Egan KP, Hook LM, Naughton A, Pardi N,
Awasthi S, Cohen GH, Weissman D and Friedman HM: An HSV-2
nucleoside-modified mRNA genital herpes vaccine containing
glycoproteins gC, gD, and gE protects mice against HSV-1 genital
lesions and latent infection. PLoS Pathog. 16:e10087952020.
View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Wollner CJ, Richner M, Hassert MA, Pinto
AK, Brien JD and Richner JM: A Dengue Virus Serotype 1 mRNA-LNP
vaccine elicits protective immune responses. J Virol. 95:e02482–20.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Wollner CJ and Richner JM: mRNA Vaccines
against Flaviviruses. Vaccines (Basel). 9:1482021. View Article : Google Scholar
|
|
114
|
Rzymski P, Szuster-Ciesielska A,
Dzieciątkowski T, Gwenzi W and Fal A: mRNA vaccines: The future of
prevention of viral infections? J Med Virol. 95:e285722023.
View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Richner JM, Himansu S, Dowd KA, Butler SL,
Salazar V, Fox JM, Julander JG, Tang WW, Shresta S, Pierson TC, et
al: Modified mRNA Vaccines Protect against Zika Virus Infection.
Cell. 169:1762017. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Parums DV: Editorial: mRNA Vaccines and
Future Epidemic, Pandemic, and Endemic Zoonotic Virus Infections.
Med Sci Monit. 27:e9329152021.PubMed/NCBI
|
|
117
|
Haynes BF: A new vaccine to battle
covid-19. N Engl J Med. 384:470–471. 2021. View Article : Google Scholar
|
|
118
|
Fairweather D, Beetler DJ, Di Florio DN,
Musigk N, Heidecker B and Cooper LT Jr: COVID-19, myocarditis and
pericarditis. Circ Res. 132:1302–1319. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Maruggi G, Chiarot E, Giovani C, Buccato
S, Bonacci S, Frigimelica E, Margarit I, Geall A, Bensi G and
Maione D: Immunogenicity and protective efficacy induced by
self-amplifying mRNA vaccines encoding bacterial antigens. Vaccine.
35:361–368. 2017. View Article : Google Scholar
|
|
120
|
Jawalagatti V, Kirthika P and Lee JH: Oral
mRNA Vaccines Against Infectious Diseases-A Bacterial Perspective
(Invited). Front Immunol. 13:8848622022. View Article : Google Scholar
|
|
121
|
Beck JD, Reidenbach D, Salomon N, Sahin U,
Türeci Ö, Vormehr M and Kranz LM: mRNA therapeutics in cancer
immunotherapy. Mol Cancer. 20:692021. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Vishweshwaraiah YL and Dokholyan NV: mRNA
vaccines for cancer immunotherapy. Front Immunol. 13:10290692022.
View Article : Google Scholar :
|
|
123
|
Wang F: Identification of tumor antigens
and immune subtypes of acute myeloid leukemia for mRNA vaccine
development. Clin Transl Oncol. 25:2204–2223. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Chung DJ, Sharma S, Rangesa M, DeWolf S,
Elhanati Y, Perica K and Young JW: Langerhans dendritic cell
vaccine bearing mRNA-encoded tumor antigens induces antimyeloma
immunity after autotransplant. Blood Adv. 6:1547–1558. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Wang S, Yang Y, Li L, Ma P, Jiang Y, Ge M,
Yu Y, Huang H, Fang Y, Jiang N, et al: Identification of Tumor
Antigens and Immune Subtypes of Malignant Mesothelioma for mRNA
Vaccine Development. Vaccines (Basel). 10:11682022. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Lin H, Wang K, Xiong Y, Zhou L, Yang Y,
Chen S, Xu P, Zhou Y, Mao R, Lv G, et al: Identification of tumor
antigens and immune subtypes of glioblastoma for mRNA vaccine
development. Front Immunol. 13:7732642022. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Zhou Q, Yan X, Zhu H, Xin Z, Zhao J, Shen
W, Yin W, Guo Y, Xu H, Zhao M, et al: Identification of three tumor
antigens and immune subtypes for mRNA vaccine development in
diffuse glioma. Theranostics. 11:9775–9790. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Xu H, Zheng X, Zhang S, Yi X, Zhang T, Wei
Q, Li H and Ai J: Tumor antigens and immune subtypes guided mRNA
vaccine development for kidney renal clear cell carcinoma. Mol
Cancer. 20:1592021. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Rojas LA, Sethna Z, Soares KC, Olcese C,
Pang N, Patterson E, Lihm J, Ceglia N, Guasp P, Chu A, et al:
Personalized RNA neoantigen vaccines stimulate T cells in
pancreatic cancer. Nature. 618:144–150. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
mRNA Vaccine Slows Melanoma Recurrence.
Cancer Discov. 13:12782023. View Article : Google Scholar
|
|
131
|
Sun Z, Jing C, Zhan H, Guo X, Suo N, Kong
F, Tao W, Xiao C, Hu D, Wang H and Jiang S: Identification of tumor
antigens and immune landscapes for bladder urothelial carcinoma
mRNA vaccine. Front Immunol. 14:10974722023. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Kiousi E, Lyraraki V, Mardiki GL, Stachika
N, Damianou AK, Malainou CP, Syrigos N, Gomatou G and Kotteas E:
Progress and Challenges of Messenger RNA Vaccines in the
Therapeutics of NSCLC. Cancers (Basel). 15:55892023. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Zheng X, Xu H, Yi X, Zhang T, Wei Q, Li H
and Ai J: Tumor-antigens and immune landscapes identification for
prostate adenocarcinoma mRNA vaccine. Mol Cancer. 20:1602021.
View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Wu Y, Li Z, Lin H and Wang H:
Identification of tumor antigens and immune subtypes of high-grade
serous ovarian cancer for mRNA vaccine development. J Cancer.
14:2655–2669. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Song J, Zhang Y, Zhou C, Zhan J, Cheng X,
Huang H, Mao S and Zong Z: The dawn of a new Era: mRNA vaccines in
colorectal cancer immunotherapy. Int Immunopharmacol.
132:1120372024. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Sumi T, Koshino Y, Michimata H, Nagayama
D, Watanabe H, Yamada Y and Chiba H: Cytokine release syndrome in a
patient with non-small cell lung cancer on ipilimumab and nivolumab
maintenance therapy after vaccination with the mRNA-1273 vaccine: A
case report. Transl Lung Cancer Res. 11:1973–1976. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Rausch S, Schwentner C, Stenzl A and Bedke
J: mRNA vaccine CV9103 and CV9104 for the treatment of prostate
cancer. Hum Vaccin Immunother. 10:3146–3152. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Liu L, Wang Y, Miao L, Liu Q, Musetti S,
Li J and Huang L: Combination Immunotherapy of MUC1 mRNA
Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of
Triple Negative Breast Cancer. Mol Ther. 26:45–55. 2018. View Article : Google Scholar :
|
|
139
|
Liu C, Papukashvili D, Dong Y, Wang X, Hu
X, Yang N, Cai J, Xie F, Rcheulishvili N and Wang PG:
Identification of Tumor Antigens and Design of mRNA vaccine for
colorectal cancer based on the immune subtype. Front Cell Dev Biol.
9:7835272022. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Huang X, Zhang G, Tang TY, Gao X and Liang
TB: Personalized pancreatic cancer therapy: From the perspective of
mRNA vaccine. Mil Med Res. 9:532022.PubMed/NCBI
|
|
141
|
Samuel N and Hudson TJ: The molecular and
cellular heterogeneity of pancreatic ductal adenocarcinoma. Nat Rev
Gastroenterol Hepatol. 9:77–87. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Makohon-Moore AP, Zhang M, Reiter JG,
Bozic I, Allen B, Kundu D, Chatterjee K, Wong F, Jiao Y, Kohutek
ZA, et al: Limited heterogeneity of known driver gene mutations
among the metastases of individual patients with pancreatic cancer.
Nat Genet. 49:358–366. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Bear AS, Vonderheide RH and O'Hara MH:
Challenges and opportunities for pancreatic cancer immunotherapy.
Cancer Cell. 38:788–802. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Kang N, Zhang S and Wang Y: A personalized
mRNA vaccine has exhibited potential in the treatment of pancreatic
cancer. Holist Integr Oncol. 2:182023. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Tan H, Yu T, Liu C, Wang Y, Jing F, Ding
Z, Liu J and Shi H: Identifying tumor antigens and immuno-subtyping
in colon adenocarcinoma to facilitate the development of mRNA
vaccine. Cancer Med. 11:4656–4672. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Ping H, Yu W, Gong X, Tong X, Lin C, Chen
Z, Cai C, Guo K and Ke H: Analysis of melanoma tumor antigens and
immune subtypes for the development of mRNA vaccine. Invest New
Drugs. 40:1173–1184. 2022. View Article : Google Scholar :
|
|
147
|
Sittplangkoon C, Alameh MG, Weissman D,
Lin PJC, Tam YK, Prompetchara E and Palaga T: mRNA vaccine with
unmodified uridine induces robust type I interferon-dependent
anti-tumor immunity in a melanoma model. Front Immunol.
13:9830002022. View Article : Google Scholar :
|
|
148
|
Li RQ, Wang W, Yan L, Song LY, Guan X,
Zhang W and Lian J: Identification of tumor antigens and immune
subtypes in breast cancer for mRNA vaccine development. Front
Oncol. 12:9737122022. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Niemi JVL, Sokolov AV and Schioth HB:
Neoantigen vaccines; clinical trials, classes, indications,
adjuvants and combinatorial treatments. Cancers (Basel).
14:51632022. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Oberli MA, Reichmuth AM, Dorkin JR,
Mitchell MJ, Fenton OS, Jaklenec A, Anderson DG, Langer R and
Blankschtein D: Lipid Nanoparticle Assisted mRNA delivery for
potent cancer immunotherapy. Nano Lett. 17:1326–1335. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Pardoll DM: The blockade of immune
checkpoints in cancer immunotherapy. Nat Rev Cancer. 12:252–264.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Mellor AL, Keskin DB, Johnson T, Chandler
P and Munn DH: Cells expressing indoleamine 2,3-dioxygenase inhibit
T cell responses. J Immunol. 168:3771–3776. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Mellman I, Coukos G and Dranoff G: Cancer
immunotherapy comes of age. Nature. 480:480–489. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Conry RM, LoBuglio AF, Wright M, Sumerel
L, Pike MJ, Johanning F, Benjamin R, Lu D and Curiel DT:
Characterization of a messenger RNA polynucleotide vaccine vector.
Cancer Res. 55:1397–1400. 1995.PubMed/NCBI
|
|
155
|
Huang X, Tang T, Zhang G and Liang T:
Identification of tumor antigens and immune subtypes of
cholangiocarcinoma for mRNA vaccine development. Mol Cancer.
20:502021. View Article : Google Scholar :
|
|
156
|
Guo Y, Lei K and Tang L: Neoantigen
Vaccine delivery for personalized anticancer immunotherapy. Front
Immunol. 9:14992018. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Grabbe S, Haas H, Diken M, Kranz LM,
Langguth P and Sahin U: Translating nanoparticulate-personalized
cancer vaccines into clinical applications: Case study with
RNA-lipoplexes for the treatment of melanoma. Nanomedicine (Lond).
11:2723–2734. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Esprit A, de Mey W, Bahadur Shahi R,
Thielemans K, Franceschini L and Breckpot K: Neo-Antigen mRNA
Vaccines. Vaccines (Basel). 8:7762020. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Blass E and Ott PA: Advances in the
development of personalized neoantigen-based therapeutic cancer
vaccines. Nat Rev Clin Oncol. 18:215–229. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Cafri G, Gartner JJ, Zaks T, Hopson K,
Levin N, Paria BC, Parkhurst MR, Yossef R, Lowery FJ and Jafferji
MS: mRNA vaccine-induced neoantigen-specific T cell immunity in
patients with gastrointestinal cancer. J Clin Invest.
130:5976–5988. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Roberts ND, Kortschak RD, Parker WT,
Schreiber AW, Branford S, Scott HS, Glonek G and Adelson DL: A
comparative analysis of algorithms for somatic SNV detection in
cancer. Bioinformatics. 29:2223–2230. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Karasaki T, Nagayama K, Kuwano H, Nitadori
JI, Sato M, Anraku M, Hosoi A, Matsushita H, Takazawa M, Ohara O,
et al: Prediction and prioritization of neoantigens: integration of
RNA sequencing data with whole-exome sequencing. Cancer Sci.
108:170–177. 2017. View Article : Google Scholar :
|
|
163
|
Horak P, Frohling S and Glimm H:
Integrating next-generation sequencing into clinical oncology:
strategies, promises and pitfalls. ESMO Open. 1:e0000942016.
View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Bassani-Sternberg M, Bräunlein E, Klar R,
Engleitner T, Sinitcyn P, Audehm S, Straub M, Weber J,
Slotta-Huspenina J, Specht K, et al: Direct identification of
clinically relevant neoepitopes presented on native human melanoma
tissue by mass spectrometry. Nat Commun. 7:134042016. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Kongsted P, Borch TH, Ellebaek E, Iversen
TZ, Andersen R, Met Ö, Hansen M, Lindberg H, Sengeløv L and Svane
IM: Dendritic cell vaccination in combination with docetaxel for
patients with metastatic castration-resistant prostate cancer: A
randomized phase II study. Cytotherapy. 19:500–513. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Ingels J, De Cock L, Mayer RL, Devreker P,
Weening K, Heyns K, Lootens N, De Smet S, Brusseel M, De Munter S,
et al: Small-scale manufacturing of neoantigen-encoding messenger
RNA for early-phase clinical trials. Cytotherapy. 24:213–222. 2022.
View Article : Google Scholar
|
|
167
|
Sahin U, Derhovanessian E, Miller M, Kloke
BP, Simon P, Löwer M, Bukur V, Tadmor AD, Luxemburger U, Schrörs B,
et al: Personalized RNA mutanome vaccines mobilize poly-specific
therapeutic immunity against cancer. Nature. 547:222–226. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Steitz J, Britten CM, Wölfel T and Tüting
T: Effective induction of anti-melanoma immunity following genetic
vaccination with synthetic mRNA coding for the fusion protein
EGFP.TRP2. Cancer Immunol Immunother. 55:246–253. 2006. View Article : Google Scholar
|
|
169
|
Weide B, Pascolo S, Scheel B,
Derhovanessian E, Pflugfelder A, Eigentler TK, Pawelec G, Hoerr I,
Rammensee HG and Garbe C: Direct injection of protamine-protected
mRNA: results of a phase 1/2 vaccination trial in metastatic
melanoma patients. J Immunother. 32:498–507. 2009. View Article : Google Scholar
|
|
170
|
Mai Y, Guo J, Zhao Y, Ma S, Hou Y and Yang
J: Intranasal delivery of cationic liposome-protamine complex mRNA
vaccine elicits effective anti-tumor immunity. Cell Immunol.
354:1041432020. View Article : Google Scholar
|
|
171
|
Sahin U, Oehm P, Derhovanessian E,
Jabulowsky RA, Vormehr M, Gold M, Maurus D, Schwarck-Kokarakis D,
Kuhn AN, Omokoko T, et al: An RNA vaccine drives immunity in
checkpoint-inhibitor-treated melanoma. Nature. 585:107–112. 2020.
View Article : Google Scholar
|
|
172
|
Conlon KC, Miljkovic MD and Waldmann TA:
Cytokines in the Treatment of Cancer. J Interferon Cytokine Res.
39:6–21. 2019. View Article : Google Scholar :
|
|
173
|
Di Trani CA, Fernandez-Sendin M, Cirella
A, Segués A, Olivera I, Bolaños E, Melero I and Berraondo P:
Advances in mRNA-based drug discovery in cancer immunotherapy.
Expert Opin Drug Discov. 17:41–53. 2022. View Article : Google Scholar
|
|
174
|
Komel T, Bosnjak M, Kranjc Brezar S, De
Robertis M, Mastrodonato M, Scillitani G, Pesole G, Signori E,
Sersa G and Cemazar M: Gene electrotransfer of IL-2 and IL-12
plasmids effectively eradicated murine B16.F10 melanoma.
Bioelectrochemistry. 141:1078432021. View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Etxeberria I, Bolaños E, Quetglas JI, Gros
A, Villanueva A, Palomero J, Sánchez-Paulete AR, Piulats JM,
Matias-Guiu X, Olivera I, et al: Intratumor Adoptive Transfer of
IL-12 mRNA Transiently Engineered Antitumor CD8(+) T Cells. Cancer
Cell. 36:613–629 e7. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Hewitt SL, Bailey D, Zielinski J, Apte A,
Musenge F, Karp R, Burke S, Garcon F, Mishra A, Gurumurthy S, et
al: Intratumoral IL12 mRNA Therapy Promotes TH1 transformation of
the tumor microenvironment. Clin Cancer Res. 26:6284–6298. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Hotz C, Wagenaar TR, Gieseke F, Bangari
DS, Callahan M, Cao H, Diekmann J, Diken M, Grunwitz C, Hebert A,
et al: Local delivery of mRNA-encoded cytokines promotes antitumor
immunity and tumor eradication across multiple preclinical tumor
models. Sci Transl Med. 13:eabc78042021. View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Hewitt SL, Bai A, Bailey D, Ichikawa K,
Zielinski J, Karp R, Apte A, Arnold K, Zacharek SJ, Iliou MS, et
al: Durable anticancer immunity from intratumoral administration of
IL-23, IL-36ү, and OX40L mRNAs. Sci Transl Med. 11:eaat91432019.
View Article : Google Scholar
|
|
179
|
Loomis KH, Lindsay KE, Zurla C, Bhosle SM,
Vanover DA, Blanchard EL, Kirschman JL, Bellamkonda RV and
Santangelo PJ: In Vitro Transcribed mRNA vaccines with programmable
stimulation of innate immunity. Bioconjug Chem. 29:3072–3083. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Jansen Y, Kruse V, Corthals J, Schats K,
van Dam PJ, Seremet T, Heirman C, Brochez L, Kockx M, Thielemans K
and Neyns B: A randomized controlled phase II clinical trial on
mRNA electroporated autologous monocyte-derived dendritic cells
(TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma
patients who are disease-free following the resection of
macrometastases. Cancer Immunol Immunother. 69:2589–2598. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
181
|
Schlake T, Thran M, Fiedler K, Heidenreich
R, Petsch B and Fotin-Mleczek M: mRNA: A novel avenue to antibody
therapy? Mol Ther. 27:773–784. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
182
|
Thran M, Mukherjee J, Pönisch M, Fiedler
K, Thess A, Mui BL, Hope MJ, Tam YK, Horscroft N, Heidenreich R, et
al: mRNA mediates passive vaccination against infectious agents,
toxins, and tumors. EMBO Mol Med. 9:1434–1447. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Dahlen E, Veitonmaki N and Norlen P:
Bispecific antibodies in cancer immunotherapy. Ther Adv Vaccines
Immunother. 6:3–17. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
184
|
Thomas A, Teicher BA and Hassan A:
Antibody-drug conjugates for cancer therapy. Lancet Oncol.
17:e254–e262. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
185
|
Page DB, Postow MA, Callahan MK, Allison
JP and Wolchok JD: Immune modulation in cancer with antibodies.
Annu Rev Med. 65:185–202. 2014. View Article : Google Scholar
|
|
186
|
Hudis CA: Trastuzumab-mechanism of action
and use in clinical practice. N Engl J Med. 357:39–51. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
187
|
Diamantis N and Banerji U: Antibody-drug
conjugates-an emerging class of cancer treatment. Br J Cancer.
114:362–367. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
188
|
de Miguel D, Lemke J, Anel A, Walczak H
and MartinezLostao L: Onto better TRAILs for cancer treatment. Cell
Death Differ. 23:733–747. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
189
|
Salles G, Barrett M, Foà R, Maurer J,
O'Brien S, Valente N, Wenger M and Maloney DG: Rituximab in B-Cell
Hematologic Malignancies: A review of 20 years of clinical
experience. Adv Ther. 34:2232–2273. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
190
|
Van Hoecke L, Verbeke R, Dewitte H,
Lentacker I, Vermaelen K, Breckpot K and Van Lint S: mRNA in cancer
immunotherapy: Beyond a source of antigen. Mol Cancer. 20:482021.
View Article : Google Scholar : PubMed/NCBI
|
|
191
|
Rybakova Y, Kowalski PS, Huang Y, Gonzalez
JT, Heartlein MW, DeRosa F, Delcassian D and Anderson DG: mRNA
Delivery for Therapeutic Anti-HER2 antibody expression in vivo. Mol
Ther. 27:1415–1423. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
192
|
Ballesteros-Briones MC, Martisova E,
Casales E, Silva-Pilipich N, Buñuales M, Galindo J, Mancheño U,
Gorraiz M, Lasarte JJ, Kochan G, et al: Short-Term Local Expression
of a PD-L1 Blocking Antibody from a Self-Replicating RNA Vector
induces potent antitumor responses. Mol Ther. 27:1892–1905. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
193
|
Nisonoff A, Wissler FC and Lipman LN:
Properties of the major component of a peptic digest of rabbit
antibody. Science. 132:1770–1771. 1960. View Article : Google Scholar : PubMed/NCBI
|
|
194
|
Wang Y, Tiruthani K, Li S, Hu M, Zhong G,
Tang Y, Roy S, Zhang L, Tan J, Liao C and Liu R: mRNA delivery of a
bispecific single-domain antibody to polarize tumor-associated
macrophages and synergize immunotherapy against liver malignancies.
Adv Mater. 33:e20076032021. View Article : Google Scholar : PubMed/NCBI
|
|
195
|
Fudenberg HH, Drews G and Nisonoff A:
Serologic demonstration of dual specificity of rabbit bivalent
hybrid antibody. J Exp Med. 119:151–166. 1964. View Article : Google Scholar : PubMed/NCBI
|
|
196
|
Garber K: Bispecific antibodies rise
again. Nat Rev Drug Discov. 13:799–801. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
197
|
Wu L, Wang W, Tian J, Qi C, Cai Z, Yan W,
Xuan S and Shang A: Engineered mRNA-expressed bispecific antibody
prevent intestinal cancer via lipid nanoparticle delivery.
Bioengineered. 12:12383–12393. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
198
|
Zhao Y, Moon E, Carpenito C, Paulos CM,
Liu X, Brennan AL, Chew A, Carroll RG, Scholler J, Levine BL, et
al: Multiple injections of electroporated autologous T cells
expressing a chimeric antigen receptor mediate regression of human
disseminated tumor. Cancer Res. 70:9053–9061. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
199
|
Rabinovich PM, Komarovskaya ME, Wrzesinski
SH, Alderman JL, Budak-Alpdogan T, Karpikov A, Guo H, Flavell RA,
Cheung NK, Weissman SM and Bahceci E: Chimeric receptor mRNA
transfection as a tool to generate antineoplastic lymphocytes. Hum
Gene Ther. 20:51–61. 2009. View Article : Google Scholar
|
|
200
|
Morgan RA, Yang JC, Kitano M, Dudley ME,
Laurencot CM and Rosenberg SA: Case report of a serious adverse
event following the administration of T cells transduced with a
chimeric antigen receptor recognizing ERBB2. Mol Ther. 18:843–851.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
201
|
Brentjens R, Yeh R, Bernal Y, Riviere I
and Sadelain M: Treatment of chronic lymphocytic leukemia with
genetically targeted autologous T cells: Case report of an
unforeseen adverse event in a phase I clinical trial. Mol Ther.
18:666–668. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
202
|
Miliotou AN and Papadopoulou LC: CAR
T-cell Therapy: A new era in cancer immunotherapy. Curr Pharm
Biotechnol. 19:5–18. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
203
|
Fiedler K, Lazzaro S, Lutz J, Rauch S and
Heidenreich R: mRNA cancer vaccines. Recent Results Cancer Res.
209:61–85. 2016. View Article : Google Scholar
|
|
204
|
Soundara Rajan T, Gugliandolo A, Bramanti
P and Mazzon E: In Vitro-Transcribed mRNA Chimeric Antigen Receptor
T Cell (IVT mRNA CAR T) therapy in hematologic and solid tumor
management: A preclinical update. Int J Mol Sci. 21:65142020.
View Article : Google Scholar : PubMed/NCBI
|
|
205
|
Zhao Y, Zheng Z, Cohen CJ, Gattinoni L,
Palmer DC, Restifo NP, Rosenberg SA and Morgan RA: High-efficiency
transfection of primary human and mouse T lymphocytes using RNA
electroporation. Mol Ther. 13:151–159. 2006. View Article : Google Scholar
|
|
206
|
Yoon SH, Lee JM, Woo SJ, Park MJ, Park JS,
Kim HS, Park MY, Sohn HJ and Kim TG: Transfer of Her-2/neu
specificity into cytokine-induced killer (CIK) cells with RNA
encoding chimeric immune receptor (CIR). J Clin Immunol.
29:806–814. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
207
|
Schaft N, Dörrie J, Müller I, Beck V,
Baumann S, Schunder T, Kämpgen E and Schuler G: A new way to
generate cytolytic tumor-specific T cells: Electroporation of RNA
coding for a T cell receptor into T lymphocytes. Cancer Immunol
Immunother. 55:1132–1141. 2006. View Article : Google Scholar
|
|
208
|
Boissel L, Betancur M, Wels WS, Tuncer H
and Klingemann H: Transfection with mRNA for CD19 specific chimeric
antigen receptor restores NK cell mediated killing of CLL cells.
Leuk Res. 33:1255–1259. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
209
|
Kenderian SS, Ruella M, Shestova O,
Klichinsky M, Aikawa V, Morrissette JJ, Scholler J, Song D, Porter
DL, Carroll M, et al: CD33-specific chimeric antigen receptor T
cells exhibit potent preclinical activity against human acute
myeloid leukemia. Leukemia. 29:1637–1647. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
210
|
Birkholz K, Hombach A, Krug C, Reuter S,
Kershaw M, Kämpgen E, Schuler G, Abken H, Schaft N and Dörrie J:
Transfer of mRNA encoding recombinant immunoreceptors reprograms
CD4+ and CD8+ T cells for use in the adoptive immunotherapy of
cancer. Gene Ther. 16:596–604. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
211
|
Barrett DM, Zhao Y, Liu X, Jiang S,
Carpenito C, Kalos M, Carroll RG, June CH and Grupp SA: Treatment
of advanced leukemia in mice with mRNA engineered T cells. Hum Gene
Ther. 22:1575–1586. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
212
|
Ang WX, Li Z, Chi Z, Du SH, Chen C, Tay
JC, Toh HC, Connolly JE, Xu XH and Wang S: Intraperitoneal
immunotherapy with T cells stably and transiently expressing
anti-EpCAM CAR in xenograft models of peritoneal carcinomatosis.
Oncotarget. 8:13545–13559. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
213
|
Almasbak H, Rian E, Hoel HJ, Pulè M,
Wälchli S, Kvalheim G, Gaudernack G and Rasmussen AM: Transiently
redirected T cells for adoptive transfer. Cytotherapy. 13:629–640.
2011. View Article : Google Scholar
|
|
214
|
Miliotou AN and Papadopoulou LC: In
Vitro-Transcribed (IVT)-mRNA CAR Therapy Development. Methods Mol
Biol. 2086:87–117. 2020. View Article : Google Scholar
|
|
215
|
Foster JB, Choudhari N, Perazzelli J,
Storm J, Hofmann TJ, Jain P, Storm PB, Pardi N, Weissman D,
Waanders AJ, et al: Purification of mRNA Encoding Chimeric Antigen
Receptor Is Critical for Generation of a Robust T-Cell Response.
Hum Gene Ther. 30:168–178. 2019. View Article : Google Scholar :
|
|
216
|
Jetani H, Navarro-Bailón A, Maucher M,
Frenz S, Verbruggen C, Yeguas A, Vidriales MB, González M, Rial
Saborido J, Kraus S, et al: Siglec-6 is a novel target for CAR
T-cell therapy in acute myeloid leukemia. Blood. 138:1830–1842.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
217
|
Lin L, Cho SF, Xing L, Wen K, Li Y, Yu T,
Hsieh PA, Chen H, Kurtoglu M, Zhang Y, et al: Preclinical
evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of
multiple myeloma. Leukemia. 35:752–763. 2021. View Article : Google Scholar
|
|
218
|
Bontkes HJ, Kramer D, Ruizendaal JJ,
Meijer CJ and Hooijberg E: Tumor associated antigen and
interleukin-12 mRNA transfected dendritic cells enhance effector
function of natural killer cells and antigen specific T-cells. Clin
Immunol. 127:375–384. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
219
|
Wilgenhof S, Van Nuffel AMT, Benteyn D,
Corthals J, Aerts C, Heirman C, Van Riet I, Bonehill A, Thielemans
K and Neyns B: A phase IB study on intravenous synthetic mRNA
electroporated dendritic cell immunotherapy in pretreated advanced
melanoma patients. Ann Oncol. 24:2686–2693. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
220
|
Figlin RA, Tannir NM, Uzzo RG, Tykodi SS,
Chen DYT, Master V, Kapoor A, Vaena D, Lowrance W, Bratslavsky G,
et al: Results of the ADAPT Phase 3 Study of Rocapuldencel-T in
combination with sunitinib as first-line therapy in patients with
metastatic renal cell carcinoma. Clin Cancer Res. 26:2327–2336.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
221
|
Van Hoecke L, Van Lint S, Roose K, Van
Parys A, Vandenabeele P, Grooten J, Tavernier J, De Koker S and
Saelens X: Treatment with mRNA coding for the necroptosis mediator
MLKL induces antitumor immunity directed against neo-epitopes. Nat
Commun. 9:34172018. View Article : Google Scholar : PubMed/NCBI
|
|
222
|
Trepotec Z, Lichtenegger E, Plank C, Aneja
MK and Rudolph C: Delivery of mRNA therapeutics for the treatment
of hepatic diseases. Mol Ther. 27:794–802. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
223
|
Sahu I, Haque AKMA, Weidensee B, Weinmann
P and Kormann MSD: Recent Developments in mRNA-Based protein
supplementation therapy to target lung diseases. Mol Ther.
27:803–823. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
224
|
Patel S, Ryals RC, Weller KK, Pennesi ME
and Sahay G: Lipid nanoparticles for delivery of messenger RNA to
the back of the eye. J Control Release. 303:91–100. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
225
|
Magadum A, Kaur K and Zangi L: mRNA-Based
protein replacement therapy for the heart. Mol Ther. 27:785–793.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
226
|
Lescan M, Perl RM, Golombek S, Pilz M,
Hann L, Yasmin M, Behring A, Keller T, Nolte A, Gruhn F, et al: De
Novo Synthesis of elastin by exogenous delivery of synthetic
modified mRNA into Skin and Elastin-Deficient Cells. Mol Ther
Nucleic Acids. 11:475–484. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
227
|
Baba M, Itaka K, Kondo K, Yamasoba T and
Kataoka K: Treatment of neurological disorders by introducing mRNA
in vivo using polyplex nanomicelles. J Control Release. 201:41–48.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
228
|
Kormann MS, Hasenpusch G, Aneja MK, Nica
G, Flemmer AW, Herber-Jonat S, Huppmann M, Mays LE, Illenyi M,
Schams A, et al: Expression of therapeutic proteins after delivery
of chemically modified mRNA in mice. Nat Biotechnol. 29:154–157.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
229
|
Van Hoecke L and Roose K: How mRNA
therapeutics are entering the monoclonal antibody field. J Transl
Med. 17:542019. View Article : Google Scholar : PubMed/NCBI
|
|
230
|
Raab M, Kostova I, Peña-Llopis S, Fietz D,
Kressin M, Aberoumandi SM, Ullrich E, Becker S, Sanhaji M and
Strebhardt K: Rescue of p53 functions by in vitro-transcribed mRNA
impedes the growth of high-grade serous ovarian cancer. Cancer
Commun (Lond). 44:101–126. 2024. View Article : Google Scholar
|
|
231
|
Yin H, Kauffman KJ and Anderson DG:
Delivery technologies for genome editing. Nat Rev Drug Discov.
16:387–399. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
232
|
Cox DB, Platt RJ and Zhang F: Therapeutic
genome editing: Prospects and challenges. Nat Med. 21:121–131.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
233
|
Wang SW, Gao C, Zheng YM, Yi L, Lu JC,
Huang XY, Cai JB, Zhang PF, Cui YH and Ke AW: Current applications
and future perspective of CRISPR/Cas9 gene editing in cancer. Mol
Cancer. 21:572022. View Article : Google Scholar : PubMed/NCBI
|
|
234
|
Ling K, Dou Y, Yang N, Deng L, Wang Y, Li
Y, Yang L, Chen C, Jiang L, Deng Q, et al: Genome editing mRNA
nanotherapies inhibit cervical cancer progression and regulate the
immunosuppressive microenvironment for adoptive T-cell therapy. J
Control Release. 360:496–513. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
235
|
Jo JI, Gao JQ and Tabata Y:
Biomaterial-based delivery systems of nucleic acid for regenerative
research and regenerative therapy. Regen Ther. 11:123–130. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
236
|
Kwon H, Kim M, Seo Y, Moon YS, Lee HJ, Lee
K and Lee H: Emergence of synthetic mRNA: In vitro synthesis of
mRNA and its applications in regenerative medicine. Biomaterials.
156:172–193. 2018. View Article : Google Scholar
|
|
237
|
Lin Z, Wu Y, Xu Y, Li G, Li Z and Liu T:
Mesenchymal stem cell-derived exosomes in cancer therapy
resistance: Recent advances and therapeutic potential. Mol Cancer.
21:1792022. View Article : Google Scholar : PubMed/NCBI
|
|
238
|
Ramos da Silva J, Bitencourt Rodrigues K,
Formoso Pelegrin G, Silva Sales N, Muramatsu H, de Oliveira Silva
M, Porchia BFMM, Moreno ACR, Aps LRMM, Venceslau-Carvalho AA, et
al: Single immunizations of self-amplifying or non-replicating
mRNA-LNP vaccines control HPV-associated tumors in mice. Sci Transl
Med. 15:eabn34642023. View Article : Google Scholar : PubMed/NCBI
|
